Prevention and control of hepatitis B in China

• Published in: Journal of medical virology Vol. 67; no. 3; pp. 447 - 450
• Main Authors: Sun, Zongtang, Ming, Lihua, Zhu, Xu, Lu, Jianhua
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.07.2002; Wiley-Liss
• Subjects: Biological and medical sciences; Child; Child, Preschool; China; Controlled Clinical Trials as Topic; EPI; Fundamental and applied biological sciences. Psychology; HBV; hepatitis B; Hepatitis B - prevention & control; Hepatitis B Vaccines - administration & dosage; Human viral diseases; Humans; Immunization Programs; Infant; Infant, Newborn; Infectious diseases; Medical sciences; Microbiology; National Health Programs; vaccination; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Viral diseases; Viral hepatitis; Virology; Asia; China; Human; Vaccination; Orthohepadnavirus; Hepatic disease; Epidemiology; Infection; Virus; Viral hepatitis B; Prevention; Immunoprophylaxis; Hepadnaviridae; Viral disease; Digestive diseases; Hepatitis B virus
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.10094

About 170 million Chinese are infected chronically with HBV and 10% suffer from chronic hepatitis. Around half a million Chinese die from hepatitis B caused hepatocellular carcinoma and endstage cirrhosis each year. From 1983 to the present, a controlled clinical trial involving 80,000 children on a universal hepatitis B vaccination programme to prevent chronic hepatitis, hepatocellular carcinoma, and endstage cirrhosis was implemented in Qidong, China. A pilot study demonstrated that the HBsAg rate reached the adult level before the fifth year of age, and neonatal vaccination with either plasma‐derived or recombinant hepatitis B vaccines provided a similar 75% protective efficacy against HBV infection. The high rate of follow‐up and blood tests coverage of the cohorts provided data to show 75% protection at the tenth to eleventh years of age against serum HBsAg and also against prolonged hepatic dysfunction. The strategy of controlling hepatitis B nationwide was based on the universal immunisation of newborns, beginning in cities and then the rural areas. The large‐scale vaccine source was provided by domestic plants through technology transfer, first providing plasma‐derived vaccine replaced completely by recombinant DNA vaccine in 1997. An official survey in 1999 using a cluster sampling of 25,878 children from 31 provinces reported an average coverage rate of three dose of hepatitis B vaccination of 70.7%, being higher in urban areas. The Ministry of Public Health of China has planned to integrate hepatitis B vaccination into the nationwide EPI program with Government‐provided vaccines starting January 1, 2002. J. Med. Virol. 67:447–450, 2002. © 2002 Wiley‐Liss, Inc.